Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* One of the following histologically confirmed diagnoses:~  * Chronic lymphocytic leukemia~    * Absolute lymphocytosis greater than 5,000/mm\^3~   * Morphologically mature lymphocytes with less than 55% prolymphocytes~   * Lymphocyte phenotypic expression of CD19 and CD5~   * Failed at least 1 prior regimen~      * Progressive lymphocytosis with more than 50% increase in peripheral lymphocytosis or a progressive lymph node or spleen enlargement (at least 25% enlargement or the appearance of new lymph nodes) that persists for at least 4 weeks despite concurrent or prior drug treatment OR~   * At least 1 of the following high-risk factors and not in first complete remission~= 17p deletion = 11q deletion~* Unmutated VH gene status~* p53 mutations~  * Prolymphocytic leukemia (PLL)~    * Absolute lymphocytosis greater than 5,000/mm\^3~   * Morphologically mature lymphocytes with more than 55% prolymphocytes~ * Low-grade non-Hodgkin's lymphoma~    * Small lymphocytic lymphoma~   * Follicular center lymphoma (grade I or II)~   * Diffuse (predominately small cell type)~   * Marginal zone, B-cell lymphoma~   * No transformed lymphoma~   * Failure of at least 1 prior regimen OR~   * At least 3 of the following risk factors:~* Over 60 years of age~* Performance status greater than 1~* LDH greater than normal~* More than 1 site of extranodal disease~* Disease stage III or IV~  * Mantle cell lymphoma~    * Any stage~   * Ineligible for protocol CALGB-59908~   * At least 1 prior treatment regimen~   * At least 1 of the following:~* Immunophenotypic expression of CD5 and CD19 and absence of CD23~* Cytogenetic analysis with presence of t(11;14)~* Overexpression of cyclin D1~* Rearrangement of BCL1 gene~  * Responsive or stable disease to most recent prior therapy~    * Prior therapy for PLL not required~ * Must have HLA identical sibling (6/6) donor by serologic typing (A, B, DR)~    * No syngeneic donors~   * No age restriction NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* Under 70~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 500/mm\^3\*~* Platelet count at least 50,000/mm\^3\* NOTE: \*Unless attributable to disease~Hepatic:~* Bilirubin no greater than 3 times upper limit of normal (ULN)\*~* AST no greater than 3 times ULN\* NOTE: \*Unless attributable to disease~Renal:~* Creatinine clearance at least 40 mL/min, unless attributable to disease~Cardiovascular:~* LVEF at least 30% by MUGA~Pulmonary:~* DLCO greater than 40%~* No symptomatic pulmonary disease~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No uncontrolled diabetes mellitus~* No active serious infection~* No known hypersensitivity to E. coli-derived products~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior autologous transplantation~Chemotherapy:~* At least 4 weeks since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy~Surgery:~* At least 4 weeks since prior surgery

- Gender: ALL
- Minimum Age: None
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Allogeneic Stem Cell Tx (Type: EXPERIMENTAL): minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).